Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News

HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503

News All Time

HTTP error: 503 HTTP error: 503
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For incarcerated people, study shows gaps exist in quality of cancer care

2.

Video: How to treat kidney disease?

3.

FDA Expands Approval of Osimertinib in Lung Cancer

4.

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

5.

Despite Medicare Coverage, Cancer Genomic Testing Still Low


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot